Benefit of Eculizumab Compared to Standard of Care Still Unproven in C3 Glomerulopathy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: W.B. Saunders Country of Publication: United States NLM ID: 8110075 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1523-6838 (Electronic) Linking ISSN: 02726386 NLM ISO Abbreviation: Am J Kidney Dis Subsets: MEDLINE
    • Publication Information:
      Publication: Philadelphia Pa : W.B. Saunders
      Original Publication: New York, N.Y. : Grune & Stratton, c1981-
    • Subject Terms:
      Glomerulonephritis, Membranoproliferative* ; Kidney Diseases*; Antibodies, Monoclonal, Humanized ; Humans ; Standard of Care
    • Comments:
      Comment on: Am J Kidney Dis. 2018 Jul;72(1):84-92. (PMID: 29429752)
      Comment in: Am J Kidney Dis. 2018 Dec;72(6):906-907. (PMID: 30236629)
    • Accession Number:
      0 (Antibodies, Monoclonal, Humanized)
      A3ULP0F556 (eculizumab)
    • Publication Date:
      Date Created: 20180922 Date Completed: 20190830 Latest Revision: 20200511
    • Publication Date:
      20231215
    • Accession Number:
      10.1053/j.ajkd.2018.07.013
    • Accession Number:
      30236630